| Theme | Update on Pancreatic Neuroendocrine Tumors | |
|---|---|---|
| Title | Surgical Treatment | |
| Publish Date | 2018/08 | |
| Author | Atsushi Kudo | Department of Hepato-biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University |
| Author | Hiroaki Ono | Department of Hepato-biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University |
| Author | Kosuke Ogawa | Department of Hepato-biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University |
| Author | Yusuke Mitsunori | Department of Hepato-biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University |
| Author | Daisuke Ban | Department of Hepato-biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University |
| Author | Minoru Tanabe | Department of Hepato-biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University |
| [ Summary ] | Since the WHO classification defined the malignant potential in 2010, the role of surgical resection in the treatment strategies of pancreatic neuroendocrine tumors changed dramatically. Every time a new medication therapy is introduced, the indication for surgical treatment has been extensively expanded. Since 2011, molecular target therapies such as everolimus, sunitinib, streptozocin, and somatostatin analogue are applied alternatively for assurance, and it has been experienced commonly that tumors considered to be unresectable previously turned out to be resectable. In 2017, clinical trials on radiological therapy targeted to SSTR 2 (PRRT) began. Expectedly, techniques of preoperative adjuvant therapy and weight loss surgery will also change. | |